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We read with interest the report by Lee and colleagues in 
the June issue of Arthritis Research & Th  erapy [1]. Th  e 
study compared the Disease Activity Score in 28 joints 
calculated by using C-reactive protein (DAS28-CRP) 
versus American College of Rheumatology/European 
League Against Rheumatism (ACR/EULAR) remission in 
terms of residual pain. Th  e authors stated that DAS28-
CRP remission criteria allowed for persistence of pain in 
more than 10% of patients, whereas there were very few 
com  plaints of pain among patients in ACR/EULAR
remission. Th  is is a very important ﬁ  nding as it clearly 
demon  strated incompetence of the DAS28-CRP remis-
sion criteria in deﬁ  ning remission that is meaningful for 
patients, thus encouraging transition to new ACR/
EULAR remission criteria.
One factor, however, that was not mentioned in the 
article and which may be of interest is the Disease 
Activity Score in 28 joints calculated by using erythrocyte 
sedimentation rate (DAS28-ESR). Although the DAS28-
CRP is a validated score demon  strating good correlation 
with the DAS28-ESR [2], the DAS28-CRP frequently 
results in lower scores than its erythrocyte sedimentation 
rate counterpart [2,3]. Inoue and colleagues thus suggest-
ed a diﬀ  erent cut-oﬀ   point of 2.3 for the DAS28-CRP [3]. 
Th  is tendency was also demonstrated in our cohort of 
265 rheumatoid arthritis patients taking biologics (Figure 1). 
When plotted against the DAS28-ESR, the DAS28-CRP 
resulted in lower values (below the diagonal line, 
indicating complete agreement) more often than not. 
Also noteworthy is that the DAS28-CRP is never lower 
than 0.96, which is the constant term in the following 
equation [4]:
DAS28-CRP = 0.56 × √TJC28 + 0.28 × 
√SJC28 + 0.36 × ln(CRP + 1) + 0.014 × GH + 0.96
in which TJC stands for tender joint count, SJC for 
swollen joint count, ln for natural logarithm, CRP for C-
reactive protein, and GH for global health as reported by 
the patient.
We therefore wonder whether Lee and colleagues 
performed the same analysis with DAS28-ESR remission 
criteria. We think it may be interesting to perform the 
same analysis with DAS28-ESR remission criteria or a 
stricter DAS28-CRP cut-oﬀ   point of 2.3. © 2010 BioMed Central Ltd
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Figure 1. Relationship between the Disease Activity Scores in 
28 joints calculated by using C-reactive protein and erythrocyte 
sedimentation rate. Relationship between the Disease Activity 
Score in 28 joints calculated by using C-reactive protein (DAS28-
CRP) and the Disease Activity Score in 28 joints calculated by using 
erythrocyte sedimentation rate (DAS28-ESR) in our biologic cohort.
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ACR/EULAR, American College of Rheumatology/European League Against 
Rheumatism; DAS28-CRP, Disease Activity Score in 28 joints calculated by 
using C-reactive protein; DAS28-ESR, Disease Activity Score in 28 joints 
calculated by using erythrocyte sedimentation rate.
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